^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
valacyclovir
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DNA polymerase inhibitor
Related drugs:
8d
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov)
P1/2, N=62, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
27d
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
P1, N=11, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
valacyclovir
1m
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2031 --> Jun 2031 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2031 --> Jun 2031
Trial completion date • Trial initiation date • Trial primary completion date
|
valacyclovir
2ms
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
P2, N=45, Recruiting, Candel Therapeutics, Inc. | N=30 --> 45
Enrollment change
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
2ms
A Randomized Controlled Clinical Study on Transfer Factor Oral Solution in the Treatment of Herpes Zoster (ChiCTR2600117507)
P4, N=90, Recruiting, Dermatology Hospital, Southern Medical University; Dermatology Hospital, Southern Medical University
New P4 trial
|
valacyclovir
2ms
Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy (clinicaltrials.gov)
P2, N=84, Enrolling by invitation, Instituto Oncoclinicas
New P2 trial
|
valacyclovir
3ms
Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (clinicaltrials.gov)
P3, N=100, Completed, Assiut University
New P3 trial
|
valacyclovir
3ms
ADePT: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (clinicaltrials.gov)
P1/2, N=68, Not yet recruiting, Trogenix ltd
New P1/2 trial
|
valacyclovir
3ms
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
P2, N=30, Recruiting, Candel Therapeutics, Inc.
New P2 trial
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
4ms
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, National Taiwan University Hospital
New trial • Head-to-Head
|
Valcyte (valganciclovir) • valacyclovir
6ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=17, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
Trial completion
|
valacyclovir
7ms
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030
Trial completion date • Trial initiation date • Trial primary completion date
|
valacyclovir
Share via
